Englewood Cliffs, NJ – According to filings with the U.S. Securities and Exchange Commission, Aspargo Laboratories is raising $15,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Michael Demurjian played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Aspargo Laboratories
Aspargo Laboratories, Inc. is a clinical-stage biopharmaceutical company developing patient-focused solutions and must-have medicines by combining our innovative science and technologies and FDAs 505(b)(2) approval pathway to enhance currently marketed drugs with well-known pharmacology profiles. Our company was formed for the purpose of commercializing innovative therapies qualifying for FDA approval under the section 505 b(2) regulatory approval pathway for new formulations of previously approved drugs. The company’s initial product candidate is a proprietary oral suspension spray formulation of sildenafil citrate, the active ingredient in VIAGRA. Our mission is to develop patient-focused solutions and must-have medicines by applying our innovative science and technologies to enhance currently marketed drugs with well-known pharmacology profiles.

To learn more about Aspargo Laboratories, visit http://aspargolabs.com/

Contact:
Michael Demurjian, Chief Executive Officer
201-408-4831
https://www.linkedin.com/in/michael-demurjian-02868113/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved